Skip to Content

SANDOZ 625 (Rivastigmine 6 mg)

Pill imprint SANDOZ 625 has been identified as Rivastigmine tartrate 6 mg.

Rivastigmine is used in the treatment of parkinson's disease; alzheimer's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 6 mg is not a controlled substance under the Controlled Substance Act (CSA).

Rivastigmine tartrate 6 mg SANDOZ 625
Rivastigmine tartrate 6 mg SANDOZ 625
Discount Card Promo
Rivastigmine tartrate
Imprint:
SANDOZ 625
Strength:
6 mg
Color:
Orange / Red
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Cholinesterase inhibitors
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Manufacturer:
Sandoz Pharmaceuticals Inc.
National Drug Code (NDC):
00781-2617
Inactive Ingredients:
gelatin
hypromellose
magnesium stearate
microcrystalline cellulose
ferric oxide red
silicon dioxide
titanium dioxide
ferric oxide yellow

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide